Evidence map›Paper›PMID 35397867›Full record

ArticleLancet (London, England)2022

COVID-19 vaccination and HIV-1 acquisition - Authors' reply.

Susan P Buchbinder, M Juliana McElrath, Carl Dieffenbach, Lawrence Corey

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Susan P BuchbinderBridge HIV, San Francisco Department of Public Health, San Francisco, CA 94102, USA; Department of Medicine and Department of Epidemiology, University of California, San Francisco, CA, USA. Electronic address: susan.buchbinder@sfdph.org.
M Juliana McElrathFred Hutchinson Cancer Research Institute, Seattle, WA, USA; University of Washington, Seattle, WA, USA.
Carl DieffenbachDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Lawrence CoreyFred Hutchinson Cancer Research Institute, Seattle, WA, USA; University of Washington, Seattle, WA, USA.

Funding

San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
San Francisco Vaccine and Prevention UnitU01AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI BUCHBINDER, SUSAN · 2007 to 2011
$7.3M
NIAID NIH HHS U01 AI069496NIAID NIH HHS UM1 AI069496
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19HIV-1HIV SeropositivityCOVID-19 VaccinesHumansSARS-CoV-2VaccinationCOVID-19 Vaccines

Identifiers

PMID35397867
PMCPMC8989399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.